Automate repetitive sales tasks with AI to improve productivity and sales results ✌️【Yield】✌️Start with ₹500 and experience high returns month after month. Automate repetitive sales tasks with AI to improve productivity and sales results - Flexible Part-Time Jobs ✌️【Yield】✌️Start your investment journey with ₹500. Watch your returns multiply monthly!

Automate repetitive sales tasks with AI to improve productivity and sales results ✌️【Yield】✌️Start with ₹500 and experience high returns month after month.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

Automate repetitive sales tasks with AI to improve productivity and sales results ✌️【Yield】✌️Low risk, high returns! Invest ₹500 today and grow your wealth month by month.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

Automate repetitive sales tasks with AI to improve productivity and sales results ✌️【Yield】✌️Turn ₹500 into big monthly profits. Start today with our smart investment tools!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

Automate repetitive sales tasks with AI to improve productivity and sales results ✌️【Yield】✌️Achieve up to 100% returns with just ₹500. Invest smart, earn big!The underperformance persists despite a 22.Automate repetitive sales tasks with AI to improve productivity and sales results ✌️【Yield】✌️Start small with ₹500 and get high returns with minimal risk. Perfect for beginners!